Sentence examples for weeks were achieved from inspiring English sources

ACR20 (American College of Rheumatology 20% improvement criteria) responses at 12 weeks were achieved in 42% of patients compared with 14% in the placebo group.

Therefore, EULAR response criteria at 24 weeks were achieved by 24 patients, four had a poor response and one was a non-responder.

ACR50 and ACR70 responses after 24 weeks were achieved by 28.8% and 12.4% of patients in the 8 mg/kg group (P < 0.0001 and P < 0.0002, respectively, versus control) [ 13] (1b level of Oxford evidence).

ACR20 responses at 102 weeks were achieved by approximately 40% of patients who demonstrated antibodies against infliximab at any time during the study (n = 25 of 295, or 8.5% of the total patients in this analysis) compared with 38% of patients with no antibodies against infliximab (n = 105) and 62% of patients with inconclusive antibody status (n = 165) [ 29].

ACR50 and ACR70 responses at 24 weeks were achieved by 28.8% and 12.4% of patients in the 8 mg/kg group (less than p<0.001 and less than p = 0.001, respectively, versus control), 16.8% and 5.0% in the 4 mg/kg group (less than p<0.001 and p = 0.1, respectively, versus control) and 3.8% and 1.3% in the control group.

We reported a phase I study of docetaxel plus irinotecan (DI) in patients with advanced NSCLC, in which a promising response rate of 48% and the median survival time of 48 weeks were achieved with acceptable toxicities (Masuda et al, 2000).

The most pronounced expansion during cultivation of 2 weeks was achieved in media supplemented with 12.5% horse serum plus 12.5% fetal calf serum (FCS) with stem cell factor and interleukine 3; the fold-expansion was 16.67±6.20.

Co-alignment of 140 fetal ultrasound volumes (age range: 26.0 ± 4.4 weeks) was achieved with high brain overlap and low eye localization error, regardless of gestational age or head size.

SD lasting ≥6 weeks was achieved in 80 patients (30.3%), to produce a disease control rate (DCR) of 43.9%.

Partial remission in 5 patients (11.6%) and disease stabilization in 14 patients (32.6%) for > 12 weeks was achieved.

Adequate symptomatic relief after 6 8 weeks was achieved in 84% of all patients with fructose intolerance and in 86% when fructose malabsorption was present with intolerance.